We're supporting the NHS and social care to respond quickly to the challenges of the coronavirus pandemic. We've brought together information that may help you.Everything we've said relevant to COVID-19
Rapid guidelines and evidence summaries
For these products we have waived our normal licensing requirements for international reuse or reproduction of our content. The full details are available on our terms of reuse page.
Email us with any feedback about our COVID-19 rapid guidelines and evidence summaries.
These guidelines cover:
- critical care in adults
- managing symptoms (including at the end of life) in the community
- managing suspected or confirmed pneumonia in adults in the community
- haematopoietic stem cell transplantation
- dialysis service delivery
- delivery of radiotherapy
- rheumatological autoimmune, inflammatory and metabolic bone disorders
- severe asthma
- delivery of systemic anticancer treatments.
They're developed in collaboration with NHS England and NHS Improvement and a cross-speciality clinical group, supported by the specialist societies and royal colleges.
We're using a different approach to normal in order to develop these guidelines quickly and we’re keeping them under review.
More information about other topics we're looking at and how they are prioritised is available.
Rapid evidence summaries
These will look at whether certain medicines may increase the severity or length of COVID-19 illness.
- ibuprofen and other non-steroidal anti-inflammatory drugs used to reduce temperature and ease flu-like symptoms
- angiotensin converting enzyme (ACE) inhibitors used to treat high blood pressure or heart failure.
We're also working with the Medicines and Healthcare products Regulatory Agency. Together we'll facilitate rapid review of information and advice on the safety and efficacy of treatments for COVID-19.
Medtech innovation briefings
These innovative technologies have been identified as being potentially useful during the COVID-19 pandemic:
Changes to how we work
Our guidance is produced by advisory committees that include a lot of frontline NHS staff. During this crisis we do not want to take them away from their work caring for patients.
We're reviewing all the guidance we have in development and prioritising:
- therapeutically critical topics, including all appraisals of cancer medicines
- diagnosis of COVID-19
- treatment of COVID-19.
We're working on revised timelines for all our other guidance that is not related to COVID-19 or therapeutically critical. We'll continue with development work on guidance where we can. There is some work we can do without committee engagement. We'll be in touch with our advisory committee chairs, members and stakeholders as soon as possible.
- All appraisals involving a cancer medicine (apart from most Cancer Drugs Fund reviews).
- Lung cancer (non-small-cell, EGFR and T790M positive, metastatic) - osimertinib (CDF Review of TA416) [ID1577]
- Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab [ID1583]
- Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
- Sapropterin dihydrochloride for treating phenylketonuria [ID1475]
- Andexanet alfa for reversing anticoagulation [ID1101]
- Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]
- Caplacizumab for treating adults experiencing an episode of acquired thrombotic thrombocytopenic purpura [ID1185]
- Emapalumab for treating primary haemophagocytic lymphohistiocytosis [ID1438]
- Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]
- Larotrectinib for treating advanced solid tumours with TRK fusions [ID1299]
- Entrectinib for treating NTRK fusion-positive solid tumours [ID1512]
- High-sensitivity troponin for the early rule out of acute myocardial infarction
- Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)
Interventional procedures guidance
Medical technologies guidance
Medtech innovation briefing
- Chest imaging artificial intelligence technologies
This is a rapidly changing situation and we'll keep our approach under review.
Free scientific advice
We can provide free fast track advice for researchers developing novel diagnostics or therapeutics for COVID-19.
Our scientific advice service helps companies to optimise generation of evidence required for health technology assessment.
- The UK government has guidance on their response to COVID-19
- The NHS website offers advice on how to protect yourself and recognise symptoms.
- The World Health Organization has information on the international situation.
Clinical knowledge summaries
These are concise, accessible summaries of current evidence for primary care professionals.
We've added some information about coronavirus - COVID-19 which is largely based on guidance from Public Health England.